Last reviewed · How we verify
Detemir or Glargine
Detemir and Glargine are long-acting basal insulin analogs that bind to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.
Detemir and Glargine are long-acting basal insulin analogs that bind to the insulin receptor to lower blood glucose by promoting glucose uptake and storage in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Detemir or Glargine |
|---|---|
| Also known as | Detemir, Levemir, Long acting insulin, Bed time insulin, Lantus |
| Sponsor | Institut de Recherches Cliniques de Montreal |
| Drug class | Long-acting basal insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Both are recombinant human insulin analogs designed for once or twice daily dosing in diabetes management. Detemir has a 16-carbon fatty acid chain that binds to albumin, providing a prolonged duration of action (up to 24 hours). Glargine forms microprecipitates in subcutaneous tissue that slowly release insulin, providing a relatively flat, long-acting profile (up to 24 hours or longer depending on formulation).
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Afrezza® INHALE-1 Study in Pediatrics (PHASE3)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (NA)
- Closed Loop From Onset in Type 1 Diabetes (NA)
- Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Detemir or Glargine CI brief — competitive landscape report
- Detemir or Glargine updates RSS · CI watch RSS
- Institut de Recherches Cliniques de Montreal portfolio CI